• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    W

    Wojewódzki Szpital Zespolony

    EST. 1968
    489论文总数
    3,992引用总数

    论文量&引用量时间轴

    机构学者

    论文(489)

    年份
    起
    –
    止
    排序
    1Cotadutide As an Innovative Approach to Glycemic Control and Weight Reduction in Patients with Type 2 Diabetes - A Contemporary Review
    Zuzanna Watek, Jan Szewczyk, Alicja Smolińska, Patrycja Krawczyk, Katarzyna Łysynkiewicz, Izabela Grzyb

    Background. Type 2 diabetes is a chronic metabolic disorder associated with impaired insulin secretion and insulin resistance, leading to persistent hyperglycemia and multiple complications. Despite advances in pharmacotherapy, many patients fail to achieve optimal metabolic control, highlighting the need for novel therapeutic approaches. Aim. The aim of this study was to present the current state of knowledge regarding cotadutide as a potential therapeutic option in the treatment of type 2 diabetes, with particular emphasis on its mechanism of action, clinical efficacy, and safety profile. Materials and methods. A narrative review of available literature was conducted, including clinical trials, meta-analyses, and preclinical studies evaluating the efficacy and safety of cotadutide in patients with type 2 diabetes and related metabolic disorders. Results. Cotadutide is a dual GLP-1 and glucagon agonist, that demonstrates a significant improvement regarding glycemia, body weight reduction and positive influence on metabolic parameters, in comparison to placebo. Clinical trials showed decrease in HbA1c, body weight and albuminuria, as well as potential benefits in liver and kidney function. The most common adverse effects involve the gastrointestinal tract. Conclusions. Cotadutide is a promising factor in diabetes type 2 treatment. It shows a broad spectrum of positive effects on metabolic parameters. However, further analysis and large-scale, long-term studies are required to establish its efficacy and safety.

    2026Quality in Sport(2026)
    引用
    AI阅读
    加入学术空间
    2Long-term Staged Management of an Extensive Pelvic and Right Lower-Extremity Vascular Malformation with Major Venous Abnormalities and Postprocedural Pulmonary Embolism: A Case Report
    Artem Shchebetun, Olena Abramchuk, Alina Biletska, Yuliia Fomenko, Liliia Koshlak, Olena Chiernobaievska, Katsiaryna Miliuk, Anastasiia Plakhotniuk, Maryna Postolaki, Ingrida Zamoyska

    Extensive vascular malformations involving a limb and major named veins may require repeated treatment over many years. Their abnormal venous anatomy may remain clinically important even when local symptoms are controlled, particularly when subsequent interventions are planned. We report the long-term course of a 26-year-old man with a congenital vascular malformation involving the pelvis and right lower extremity, diagnosed at 13 years of age and historically described as an arteriovenous malformation. Historical CT angiography reports described arteriovenous components together with extensive venous abnormalities, including aneurysmal dilatation of the right popliteal and external iliac veins. Staged surgery during adolescence was followed by an approximately 13-year interval without further invasive treatment, during which the patient initially remained clinically stable before gradually developing recurrent symptoms. At 26 years of age, progressive symptoms prompted combined endovenous laser treatment, electrocoagulation, and sclerotherapy. On postoperative day 7, the patient developed occlusive right popliteal venous thrombosis and acute bilateral pulmonary embolism requiring systemic thrombolysis followed by anticoagulation. The patient stabilized after treatment. At approximately 3-month cardiology follow-up, he was asymptomatic, with preserved cardiac function and good exercise tolerance. Longer-term symptom control was maintained with class III compression therapy, therapeutic exercise, and regular physical activity, with improvement in pain and lower-extremity edema. This case illustrates that major venous abnormalities may remain clinically relevant throughout the long-term course of a complex vascular malformation. In patients undergoing further intervention, lesion-specific venous anatomy and pre-existing thrombotic changes within malformed venous spaces should be considered alongside conventional peri-procedural thromboembolic risk factors. Long-term management should remain individualized and focused on symptoms, function, and surveillance of major vascular abnormalities.

    2026Radiology Case Reports(2026)
    引用
    AI阅读
    加入学术空间
    3Phase 1b/2 KEYNOTE-365 Cohort I: Pembrolizumab (pembro) Plus Carboplatin and Etoposide Chemotherapy (chemo) or Chemo Alone for Metastatic Neuroendocrine Prostate Cancer (NEPC).
    Gunhild Von Amsberg,Urban Emmenegger,Debbie G. J. Robbrecht,Cagatay Arslan,Niven Mehra,Enrique Gonzalez-Billalabeitia,Mariusz Kwiatkowski,Margitta Retz,Fatih Kose,Mark David Linch,Brigitte Laguerre,Alessandra Mosca,

    5059 Background: Patients with NEPC are often treated with platinum-based chemotherapy but novel therapies with favorable efficacy and safety profiles are needed. Cohort I of the phase 1b/2 KEYNOTE-365 study (NCT02861573) was designed to evaluate the safety and efficacy of adding pembro to chemo in participants (pts) with NEPC. Preliminary data are presented. Methods: Adultpts with pathologically (morphology and immunohistochemistry) confirmed treatment-emergent (t-NE) or de novo metastatic NEPC (small cell, large cell, or mixed morphology per central review), disease progression ≤6 mo before screening, and ECOG PS of 0 or 1, with or without prior androgen deprivation therapy, are included. Enrollment is ongoing. Prior treatment (Tx) with ≤2 chemo regimens for metastatic castration-resistant prostate cancer and ≤2 next-generation hormonal agents are allowed. Prior Tx with platinum-containing regimens is not permitted. Pts are randomly assigned 1:1 to receive 4-6 cycles of carboplatin AUC 5 IV on day 1 Q3W + etoposide 100 mg/m 2 IV on days 1-3 Q3W with or without pembro 200 mg IV Q3W for ≤35 cycles. Primary end points are safety, ORR per RECIST v1.1 by blinded independent central review (BICR), and confirmed prostate-specific antigen (PSA) response rate (≥50% decrease from baseline [BL] measured twice ≥3 wk apart). Secondary end points include rPFS per PCWG3-modified RECIST v1.1 by BICR and OS. No formal hypothesis testing was performed. Results: As of August 26, 2024, 40 pts have been randomized; 19 pts received ≥1 dose of pembro + chemo and 18 pts ≥1 dose of chemo. Of treated pts, 29 (78%) had t-NE. Median follow-up was 11.7 mo (range, 0.5-28.7); 7 and 2 pts remain on Tx with pembro + chemo or chemo, respectively. For pts with RECIST-measurable disease, confirmed ORR was 33% (6/18; 95% CI, 13-59; 6 partial responses [PRs]) with pembro + chemo versus 6% (1/16; 0-30; 1 PR) with chemo. For pts with a BL PSA measurement, confirmed PSA response rate was 37% (7/19; 95% CI, 16-62) versus 18% (3/17; 4-43). In all treated pts, median rPFS was 5.1 mo (95% CI, 3.9-8.1) with pembro + chemo versus 4.0 mo (2.0-4.3) with chemo; 6-mo rPFS rate was 49% versus 21%. Median OS was 11.4 mo (95% CI, 5.1-not reached) versus 7.8 mo (3.6-8.5); 6-mo OS rate was 80% versus 65%. Grade 3 or 4 Tx-related AEs (TRAEs) occurred in 58% of pts with pembro + chemo versus 78% with chemo, most commonly anemia (32% vs 39%); no grade 5 TRAEs occurred. Immune-mediated AEs and infusion reactions occurred in 32% of pts with pembro + chemo versus 11% with chemo, most commonly hyperthyroidism (16% vs 6%) and infusion reactions (16% vs 6%). Conclusions: Based on these preliminary data in pts with NEPC, the addition of pembro to chemo is associated with promising efficacy outcomes compared with chemo alone and does not result in new or unexpected safety signals. Updated data from cohort I will be presented at the meeting. Clinical trial information: NCT02861573 .

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)引用:2
    引用
    AI阅读
    加入学术空间
    4Skargi, Wnioski I Petycje Jako Forma Partycypacji W Samorządzie Terytorialnym
    Jarosław Dolny

    Konstytucja RP w art. 63 stanowi o prawie każdego do składania skarg, wniosków i petycji do organów władzy publicznej oraz do organizacji i instytucji społecznych w związku z wykonywaniem przez nie zadań zleconych z zakresu administracji publicznej. Pomiędzy powołanym prawem a partycypacją w samorządzie terytorialnym istnieje ścisły związek, gdyż mieszkańcy, wnosząc skargi, wnioski czy petycje do organów jednostek samorządu terytorialnego, angażują te podmioty w wykonywanie określonych działań. W niniejszym artykule autor scharakteryzował to prawo, przedstawił jego funkcje oraz podjął próbę odpowiedzi na pytanie, czy obecna regulacja prawna jest wystarczająca w kontekście partycypacji społeczeństwa w samorządzie terytorialnym, czy też wymaga odpowiednich zmian.

    2025Rocznik Administracji Publicznej(2025)
    引用
    AI阅读
    加入学术空间
    5Basic Direct Testing Methods Used in Laboratory Medical Parasitology
    Beata Szostakowska, Hanna Żarnowska-Prymek, Roland Wesołowski

    The basic condition for well-conducted microscopic parasitological diagnostics is the correct preparation of preparations intended for evaluation. The article contains detailed, accessible instructions on examination methods, including the correct preparation of smears: blood, bone marrow, and stool intended for direct parasitological examinations. It also presents the most important methods of staining these materials, tested by us, and instructions for the preparation of basic fixatives used in parasitological examinations. It also describes the most commonly used methods of in vitro culture of intestinal nematode larvae and amphizoic amoebas. In addition, it describes how to view the prepared preparations, and the notes and comments contain practical advice and explanations of some procedures for diagnosticians performing the examinations. The information contained in the work should be helpful, especially for less experienced diagnosticians, in their daily practice in parasitological medical laboratories.

    2025Diagnostyka Laboratoryjna(2025)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 489 篇论文

    合作机构(100)

    Medical University of Lublin合作论文 19
    华沙医科大学合作论文 14
    Fryderyk Chopin University of Music合作论文 13
    Jan Kochanowski University合作论文 13
    Rzeszów University合作论文 12
    Gdańsk Medical University合作论文 11
    Centrum Onkologii合作论文 10
    Wojewódzki Szpital Specjalistyczny we Wrocławiu合作论文 10
    Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lubartowie合作论文 10
    比亚韦斯托克医科大学合作论文 9

    机构统计